A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
about
First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meetingPancreatic Cancer from Molecular Pathways to Treatment OpinionSignal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their CrosstalksTargeting the Hedgehog Pathway in Pediatric MedulloblastomaMaintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-AnalysisThe Role of Hedgehog Signaling in Tumor Induced Bone DiseaseCooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapyHedgehog signaling pathway in ovarian cancerMolecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cellsFOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast CancerHedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete high/low clustersCan oncology recapitulate paleontology? Lessons from species extinctionsDecitabine reactivated pathways in platinum resistant ovarian cancer.Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival.Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factorsNew horizons in tumor microenvironment biology: challenges and opportunitiesTargeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical updateAlopecia in patients treated with molecularly targeted anticancer therapies.Hedgehog signaling and steroidogenesis.Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop.Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project.Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.Discovery and preclinical development of vismodegib.Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.Cancer stem cells: are they responsible for treatment failure?Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials.An overview of early investigational therapies for chemoresistant ovarian cancer.Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.Emerging from their burrow: Hedgehog pathway inhibitors for cancer.Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function.Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol.Suppressor of fused (Sufu) promotes epithelial-mesenchymal transition (EMT) in cervical squamous cell carcinoma.Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer
P2860
Q21198874-FC6E207B-A688-424E-9C81-669310085E17Q26743482-018CA509-1968-464E-95D1-D1BE15EE0217Q26752554-985B897C-1BC0-45F2-BEC7-489818F46049Q26777997-EE95006A-3D88-4BA4-B99D-29C9F90541FCQ26781561-7371D992-5087-488F-B0B9-D463451C72FCQ26783615-54E4A863-B9FF-4CFD-B160-01373A60F714Q26865136-9EE36D75-E874-4CD8-8F6D-F54A711E7C7AQ26995487-695427C4-E6A6-417F-A2CE-B6067CFA6D57Q28081405-5DC05E56-6461-4B0C-824D-3F1B96732206Q28269779-596AD84C-3D9D-45A0-9828-BAE6FA269F20Q28544108-98038FAF-4238-4F86-8359-919A3563C800Q28607703-36C36959-6215-4CFD-BB1B-BE9B801635A2Q33976957-20F2DAB4-6E1D-4272-A955-A8B6B043041DQ34653337-BDA97903-DDDA-4B7F-AED1-81A86A7D3B82Q35077800-E79C88D0-C419-484B-B787-23ED828F0201Q35151324-71D677C4-50B2-435B-AC64-461F2FB07007Q35904534-7D1D3BE1-14C4-4D54-B0A2-665CCC4FB4B4Q36316632-77B8DCED-EB53-451A-B5A2-8E60049278A0Q36765180-E7859C01-E6D3-470E-BB24-4E63D61E1112Q36916375-C3DC2442-B9C3-4B66-B275-3557637E7D6FQ37551492-313B4C0D-E3C9-477D-A80F-91AACDFEC5A9Q37653445-E7EBB0DD-6A3C-41F6-A626-F05431163612Q38164659-7189681A-B9E4-462A-A40B-F61153DF2770Q38214255-98079669-FC87-4EAD-8946-58089386DFE1Q38222277-C23A17D8-CF55-436C-A43F-FF15AC763192Q38231365-0C0C5FAF-37A1-48FD-BDB9-C7062F0A770AQ38268164-3BF0D00F-04B8-4E67-8AA2-E91C2A99B719Q38354853-06DEDFDD-1964-442A-B090-601ED91BE731Q38553247-63546FC3-B4B3-4FF7-B80A-305D880C8505Q38720111-8B873083-7D13-4728-8E40-5912467A6633Q38795323-772AC17E-AA05-4F7A-B2C1-F2911429061CQ38908981-F824FE29-8531-4183-AB85-E9031F267A8EQ39020546-0046269C-7D3B-4E28-94D9-DD57499E1E5BQ39525476-41147266-047C-4499-86B4-E677304AC371Q49234750-EEFDBBD1-05DF-4102-AA3C-AA713E7D51EFQ52431551-D0BB35AE-4A11-48F6-9AC2-1A97B56AD6C9Q57962903-BA365E84-F656-4261-9A70-BF4401E1FBE5
P2860
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A phase II, randomized, placeb ...... d or third complete remission.
@en
type
label
A phase II, randomized, placeb ...... d or third complete remission.
@en
prefLabel
A phase II, randomized, placeb ...... d or third complete remission.
@en
P2093
P1476
A phase II, randomized, placeb ...... nd or third complete remission
@en
P2093
Amnon Amit
Beth Karlan
Brian Slomovitz
Ilsung Chang
Louis Fehrenbacher
Paul Sabbatini
Robert Holloway
Robert L Yauch
Stanley B Kaye
P304
P356
10.1158/1078-0432.CCR-12-1796
P407
P577
2012-10-02T00:00:00Z